Related Experiment Video
Updated: Mar 9, 2026

Anionic Polymerization of an Amphiphilic Copolymer for Preparation of Block Copolymer Micelles Stabilized by π-π Stacking Interactions
Published on: October 10, 2016
Stabilized Polymer Micelles for the Development of IT-147, an Epothilone D Drug-Loaded Formulation
Adam Carie1, Bradford Sullivan1, Tyler Ellis1
1Intezyne Technologies, 3720 Spectrum Blvd. Ste. 104, Tampa, FL, USA.
Abstract:
Epothilones have demonstrated promising potential for oncology applications but suffer from a narrow therapeutic window. Epothilone D stabilizes microtubules leading to apoptosis, is active against multidrug-resistant cells, and is efficacious in animal tumor models despite lack of stability in rodent plasma. Clinical development was terminated in phase II due to dose limiting toxicities near the efficacious dose. Taken together, this made epothilone D attractive for encapsulation in a stabilized polymer micelle for improved safety and efficacy. We have designed a library of triblock copolymers to develop IT-147, a lead formulation of epothilone D that extends plasma circulation for accumulation in the tumor environment, and potentially decrease systemic exposure to reduce dose limiting toxicities. The drug loading efficiency for IT-147 exceeds 90%, is 75 nm in diameter, and demonstrates pH-dependent release of epothilone D without chemical conjugation or enzymatic activation. Administration of IT-147 at 20 mg/kg increases exposure of epothilone D to the plasma compartment over 6-fold compared to free drug. At the same dose, 20 mg/kg epothilone D from IT-147 is considered the no observed adverse effect level (NOAEL) but is the maximum tolerated dose for free drug. Consequently, IT-147 is positioned to be a safer, more effective means to deliver epothilone D.
Insights
Epothilone D shows cancer-fighting potential but has safety issues. Encapsulating it in polymer micelles (IT-147) improves drug delivery, enhancing efficacy and reducing toxicity for better cancer treatment.
Area of Science:
- Oncology
- Nanotechnology
- Drug Delivery
Background:
- Epothilones, like Epothilone D, are potent microtubule-stabilizing agents with anticancer activity.
- Clinical trials of Epothilone D were halted due to dose-limiting toxicities and poor plasma stability.
- Encapsulation in nanocarriers offers a strategy to improve Epothilone D's therapeutic index.
Purpose of the Study:
- To develop a novel formulation of Epothilone D using stabilized polymer micelles.
- To enhance the safety and efficacy of Epothilone D through improved drug delivery.
- To create a formulation (IT-147) that increases tumor accumulation and reduces systemic toxicity.
Main Methods:
- Designed and synthesized a library of triblock copolymers for micelle formulation.
- Characterized the Epothilone D-loaded micelles (IT-147) for size, drug loading, and release kinetics.
- Evaluated the pharmacokinetic profile and toxicity of IT-147 compared to free Epothilone D in preclinical models.
Main Results:
- IT-147 achieved high drug loading efficiency (>90%) and a particle size of 75 nm.
- The formulation demonstrated pH-dependent release of Epothilone D.
- IT-147 significantly increased Epothilone D plasma exposure (6-fold) and exhibited a higher no-observed-adverse-effect level (NOAEL) compared to the free drug.
Conclusions:
- Stabilized polymer micelles (IT-147) represent a promising platform for delivering Epothilone D.
- IT-147 enhances Epothilone D's pharmacokinetic profile and safety, potentially overcoming previous clinical limitations.
- This formulation offers a safer and more effective approach for Epothilone D-based cancer therapy.
More Related Videos
Related Concept Videos
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
Drugs that Stabilize Microtubules
Modified-Release Drug Delivery Systems: Site-Targeted
Micelles
Bioavailability Enhancement: Drug Permeability Enhancement

